

Global Healthcare  
CMO Market:  
Size and Forecast  
with  
Impact Analysis of  
Covid-19 (2020-2024)

April 2020



# Global Healthcare CMO Market Coverage

Executive Summary and Scope

Introduction/Market Overview

Global Market Analysis

Regional Analysis

Impact of Covid -19

Competitive Landscape

Company Profiles

# Global Healthcare CMO Market

## Scope of the Report

Attributes	Details
Title	Global Healthcare CMO Market: Size and Forecast with Impact Analysis of Covid-19 (2020-2024)
Coverage	Global and Regional
Regional Coverage	Asia Pacific
Forecast Period of Market	2020-2024
Competition in the Market	Fragmented
Key Players	Catalent Pharma Solution, Recipharm, Aurobindo Pharma Ltd. and Boehringer Ingelheim

# Global Healthcare CMO Market

## Executive Summary

An outsourcing in which a pharmaceutical firm contacts with a third party (contract manufacturing organization) for the manufacturing of components of its product or whole of its product is known as contract manufacturing. A contract manufacturing organization (CMO) undertakes the production of product(s) under the brand name of another firm.


A firm either big or mid-size selects a CMO for primarily two reasons: it wants to shift (or cut) its cost and focus to its core activities, or the development of its products require special or expert handling.

CMOs provide independent manufacturing services in healthcare sector also. Healthcare CMOs can be segmented into pharmaceutical CMOs and medical device CMOs. After the discovery of chemical formula of a new drug, the pharmaceutical CMOs are given the task of manufacturing it into a whole product, so that the pharmaceutical companies are able to sell it into the market under their brand name. Services offered by pharmaceutical CMOs can be divided into two main activities: primary manufacturing (Active Pharmaceutical Ingredients) and secondary manufacturing (Finished Dosage Formulation). Contract manufacturing for medical devices is one of the fastest growing segments of the medical device industry, as companies are in the race to bring new devices to the market.

The global healthcare CMO market has recorded continuous growth over the past few years and is expected to follow the same trend in coming years. The main driving factors for this growth are rise in global pharmaceutical industry, increased need for outsourcing, increased approvals and outsourcing of NMEs, innovations and increased regulatory pressure on quality. Yet there are some challenges, which healthcare CMO industry faces, such as fragmented nature of market, less preference for outsourcing of profitable and biological drugs by big pharmaceutical companies.

# Global Healthcare CMO Market Analysis


## Global Healthcare CMO Market by Value



CAGRs	
2020-2024	xx%

# Global Healthcare CMO Market Segment Analysis


**Global Healthcare CMO Market by Segments; 2019  
(Percentage,%)**



Segments	Share
Pharmaceutical CMO	xx%
Medical Device CMO	Xx%

# Global Medical Device CMO Market Analysis


## Global Medical Device CMO Market by Value



CAGRs	
2020-2024	xx%

# Global Pharmaceutical CMO Market Analysis

## Global Pharmaceutical CMO Market by Value




CAGRs	
2020-2024	xx%



# Global Pharmaceutical CMO Market Segment Analysis


Global Pharmaceutical CMO Market by Segments; 2019  
(Percentage,%)



Segments	Share
Active Pharmaceutical Ingredients (API)	xx%
Others (FDF and Packaging)	Xx%

# Global Active Pharmaceutical Ingredient CMO Market Analysis


## Global Active Pharmaceutical Ingredient CMO Market by Value



CAGRs	
2020-2024	xx%

# Asia Pacific Healthcare CMO Market Analysis

## Asia Pacific Healthcare CMO Market by Value




### CAGRs

2020-2024	xx%
-----------	-----

# Impact of Covid-19 Analysis

## Global Pharmaceutical CDMO Market by Value



CAGRs	
2020-2024	xx%

# Global Healthcare CMO Market : Competitive Landscape

## Players Profiled


- Catalent Pharma Solution,



- Recipharm



- Aurobindo Pharma Ltd.



- Boehringer Ingelheim



Note: The graphs on this slide are only for sample representation.